Setting new standards in information exchange for the pharmaceutical and biotech industry
Important Business Aspects of Immuno-Oncology: Issues and Controversies
September 28, 2017
Originally recorded during a panel session at the 2017’s Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspects of IO. He’s joined by IO360° lead advisor and SVP at GSK, Dr Axel Hoos, Dr Robert Ang of Neon Therapeutics, Dr Jeffrey Bockman from Defined Health, Dr Jeffrey Legos from Novartis Pharmaceuticals, and Dr Chandra Ramanathan at Bayer Healthcare.
Save the date for the 4th Annual IO360° conference, taking place February 7-9, 2018 in New York City.